The Team

MYELOMA TEAM

Image
Shagun Arora, MD

Shagun Arora, MD

Associate Clinical Professor, Division of Hematology/Oncology

Physician Profile

Dr. Shagun Arora is a hematologist-oncologist who specializes in caring for patients with malignant and classical (cancerous and noncancerous) blood disorders. She treats patients with diverse hematologic conditions in both categories. Her focus is monoclonal gammopathies, or conditions in which the blood contains abnormal proteins, including MGUS (monoclonal gammopathy of undetermined significance) and multiple myeloma, along with anemias. Dr. Arora is also the medical director of the Infusion Center at UCSF's Parnassus campus and leads the plasma cell dyscrasia informatics projects.

Image
Ajai Chari, MD

Ajai Chari, MD

Professor, Medicine
Director, Multiple Myeloma Program

Physician Profile

Dr. Chari’s research interests include the development of novel chemotherapy regimens, including Phase 1 and 2 studies. He is principal investigator of both investigator-initiated trials as well as national and international industry-sponsored studies. In his previous role as Director of Clinical Research in the Multiple Myeloma Program at Mt Sinai New York, he oversaw the growth of a program renowned nationally for both high volume patient accruals and rigorous quality assurance. The program played a pivotal role in the approval of each of the most recent therapies to be approved by the FDA for the treatment of multiple myeloma.


Image
Alfred Chung, MD

Alfred Chung, MD

Assistant Professor, Medicine, Division of Hematology/Oncology

Physician Profile

Dr. Alfred Chung is a hematologist-oncologist who cares for patients with plasma cell disorders, including multiple myeloma and AL amyloidosis. Dr. Chung's research centers on the development of new therapies for plasma cell disorders and is the primary investigator on several clinical trials, studying novel cellular therapies, immunotherapies, and targeted therapeutics. He has a special interest in AL amyloidosis and serves as the lead amyloid hematologist at UCSF.


Image
Anupama Kumar, MD

Anupama Kumar, MD

Assistant Professor, Medicine

Physician Profile

Dr. Anupama Kumar is a hematologist-oncologist who specializes in caring for patients with multiple myeloma and other blood cancers. She also cares for patients who are undergoing treatments that include stem cell transplant, chemotherapy and cell therapies while in the hospital.  In research, Kumar leads clinical trials evaluating new treatments for patients with multiple myeloma.


Image
Tom Martin, MD

Thomas Martin, III, MD

Clinical Professor of Medicine, Division of Hematology/Oncology
Director, Clinical Research, Hematologic Malignancies Program
Co-Leader, Cancer Immunology and Immunotherapy
Associate Director, Myeloma Program
Co-Director, Grand MMTI

Research Profile | Physician Profile

Dr. Thomas Martin is a leading expert in hematological malignancies and has been the principal investigator (PI) on over 25 MM clinical trials. His clinical research also includes translational studies designed to address the genetics of MM, the role of the microenvironment as well as discovery of biomarkers for patient selection and response to anti-MM therapeutics.


Image
Darren Pan, MD

Darren Pan, MD

Darren Pan, MD Assistant Professor, Medicine

Physician Profile

Dr. Darren Pan is a hematologist/oncologist specializing in the care of patients with multiple myeloma and other blood cancers. Dr. Pan conducts research identifying cutting-edge treatment options for patients with multiple myeloma with a focus on immunotherapies. He provides comprehensive care to patients both in the clinic and the hospital, including those undergoing bone marrow transplants and advanced cellular therapies like CAR T cell therapy.


Image
Nina Shah, MD

Nina Shah, MD

Clinical Professor Volunteer

Dr. Nina Shah is a specialist in blood diseases who focuses on treating multiple myeloma, a type of cancer affecting certain cells in the bone marrow. Her areas of professional interest include the intersection of immunology and oncology as well as helping patients fight multiple myeloma by boosting their immune systems. She previously was Professor of Clinical Medicine within UCSF’s Multiple Myeloma program. Currently, she is Global head of Multiple Myeloma Clinical Development and Strategy at AstraZeneca, but still sees patients every other week at UCSF.


Image
Jeff Wolf, MD

Jeffrey Wolf, MD

Clinical Professor of Medicine, Division of Hematology/Oncology
Director, Myeloma Program and Grand MMTI

Research Profile | Physician Profile

Dr. Jeffrey L. Wolf is a hematologist and expert in cancer of the bone marrow and blood as well as an expert in bone marrow transplantation to treat these cancers. His primary focus in both patient care and research is myeloma, including studies in the area of high-risk disease and the use of minimal residual disease (MRD) in clinical decision making.


SCIENTIFIC/TRANSLATIONAL RESEARCH TEAM

Image
Justin Eyquem, PhD

Justin Eyquem, PhD

Assistant Professor, Department of Medicine
Gladstone-UCSF Institute for Genomic Immunology 
Parker Institute for Cancer Immunotherapy

Research Profile | Lab Website

Dr. Eyquem’s research focuses on optimizing genetically modified immune T cells, known as CAR-T cells, to fight cancers and other diseases. He has pioneered methods to edit the genome of human CAR-T cells and developed techniques to reprogram their functions both outside the body (ex vivo) and inside the body (in vivo). Additionally, he leads a preclinical team dedicated at designing the most effective therapies for a UCSF clinical pipeline. Finally, he participated in multiple collaborations to facilitate the manufacturing of CAR-T cells for clinical use, including a UCSF clinical trial in Myeloma set to begin early 2025.


Image
Robert Flavell, MD, PhD

Robert Flavell, MD, PhD

Associate Professor, Radiology Chief, Molecular Imaging and Therapeutics Clinical Section, Radiology and Biomedical Imaging

Research Profile | Lab Website

Dr. Flavell’s laboratory focuses on the development of new molecular imaging and therapeutic tools for better understanding of disease progression in patients with prostate and other cancers. One area of interest is the relationship between acidic interstitial pH and disease progression, where he has developed new tools to directly image tumor pH using hyperpolarized 13C MRI and positron emission tomography (PET). Another major focus is the development of novel theranostic agents, where new therapies are paired with imaging agents against the same target. Dr. Flavell's research spans from basic chemistry and chemical biology projects to translational and clinical studies.

Image
Alex Marson, MD, PhD

Alex Marson, MD, PhD

Professor, Medicine Director, Gladstone-UCSF Institute of Genomic Immunology

Research Profile | Lab Website

Dr. Alex Marson is a physician-scientist interested in how DNA controls the behavior of cells in the human immune system. His background is focused in immune genomics and the Marson lab is focused on adapting CRISPR genome editing techniques to human immune cells in order to understand the genetic programs controlling immune cell function and to manipulate T cells to generate cell-based therapies to fight cancer, autoimmune diseases, and infectious diseases.


Image
David Oh, MD

David Oh, MD, PhD

Associate Professor in Residence, Division of Hematology/Oncology Co-Leader, Cancer Immunotherapy Program (CIP) Co-Leader, Cancer Immunotherapy Toxicity Evaluation (CITE) Clinic

Physician Profile | Lab Website

Dr. Oh is a physician-scientist focused on developing novel immunotherapies for cancer for improved outcomes. Clinically, he treats patients in the CIP Clinic, which implements first-in-human novel cellular and non-cellular immunotherapy trials. He is Co-Director of the CITE Clinic, which focuses on patients with immune toxicities after immunotherapy to provide expert clinical consultation and novel research to understand, prevent, and treat these toxicities. He also directs the Cancer Immunotherapy Laboratory (CIL) which interrogates samples from cancer patients receiving immunotherapy to uncover the components of the immune system that drive benefit, resistance, and toxicities.


Image
Brian Shy, MD, PhD

Brian Shy, MD, PhD

Medical Director, Human Islet and Cellular Transplant Facility Processing Facility Director, Pediatric Cell Therapy Lab Assistant Professor In Residence, Laboratory Medicine Director, Development and Manufacturing, Living Therapeutics Initiative

Research Profile | Lab Website

Dr. Shy’s laboratory employs cutting-edge genome and epigenome engineering techniques to develop, manufacture, and deliver advanced cell and gene therapies. Their research focuses on developing novel cellular engineering tools, increasing the safety and effectiveness of cellular products, refining manufacturing processes, and incorporating emerging delivery methods. They apply these technologies to develop better treatments for a wide variety of indications including inherited immune disorders, infectious disease, and cancer. These efforts feed directly into the pre-clinical development and GMP manufacturing pipeline to make next generation therapies rapidly available for UCSF patients.  


Image
Arun Wiita, MD, PhD

Arun Wiita, MD, PhD

Associate Professor, Laboratory Medicine
Director, Grand MMTI Translational Lab
Assistant Director, UCSF Cytogenetics Laboratory

Research Profile | Lab Website

Dr. Arun Wiita's research is focused on using mass spectrometry-based proteomics to discover new biology and therapeutic targets in hematologic malignancies (blood cancers). He leads an inter-disciplinary group that aims to integrate proteomics-based screening with “multi-omics” bioinformatics, clinical data, epigenetic methods, genome engineering, antibody engineering, cellular engineering, chemical biology, and mechanistic biology.  Recent work has focused on using proteomic methods to discover new immunotherapy targets in multiple myeloma and then integrate these discoveries with protein and cellular engineering to develop new immunotherapeutics. Additional efforts include cellular engineering and small molecule combination strategies to enhance the efficacy of existing myeloma therapies. 


Clinical Support Team

Nurse Practitioners (NP)/Physician Assistants (PA)
Grace Sevilla 
Sam Shenoy (R) 
Nancy Wong
Laura Zitella

Registered Nurses (RNs)
Jennifer Brustein
Lisa Dunn
Katharina Ganapathi
Julie Mccluggage (R)
Megan Shields (R)
Jenner Wells
Samantha Zylberman (R)

Cellular Therapy RN Coordinators
Jennifer Knoche
Gabbi Perez
Cheryl Slagle 
Stephanie Stern Blitzstein

Pharmacists
Francesca Alcala
Marisela Banez
Eileen Bang
Richard Fong
Larissa Graff
Angela Lee
Mimi Lo
Kim Makashima
Lily Yan
Rebecca Young

Medical Assistants 
Nashia Raley